Deutsche Märkte öffnen in 1 Stunde 24 Minute

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
138,41+2,96 (+2,19%)
Börsenschluss: 04:00PM EDT
137,71 -0,71 (-0,51%)
Nachbörse: 05:01PM EDT

Jazz Pharmaceuticals plc

Waterloo Exchange
Fifth Floor Waterloo Road
Dublin 4
Ireland
353 1 634 7800
https://www.jazzpharma.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter3.200

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Bruce C. CozaddCo-Founder, Chairman & CEO2,27M2,63M1964
Mr. Daniel N. Swisher Jr.Pres1,27MN/A1963
Ms. Renee D. GalaExec. VP & CFO1,03MN/A1972
Mr. Christopher John Tovey BScExec. VP, COO and MD of Europe & International880,61kN/A1965
Dr. Robert Iannone M.D.Exec. VP and Global Head of R&D983,25kN/A1967
Ms. Patricia CarrSr. VP & Chief Accounting OfficerN/AN/A1971
Dr. Finbar Larkin Ph.D.Sr. VP of Technical OperationsN/AN/A1958
Ms. Andrea N. Flynn Ph.D.VP & Head of Investor RelationsN/AN/AN/A
Ms. Neena M. Patil J.D.Exec. VP & Chief Legal OfficerN/AN/A1975
Dr. George Christopher Eliades Ph.D.Sr. VP of Corp. Devel. & Chief Transformation OfficerN/AN/A1970
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

Corporate Governance

Jazz Pharmaceuticals plcs ISS Governance QualityScore, Stand 1. Oktober 2022, lautet 3. Die grundlegenden Scores sind Audit: 5, Vorstand: 2, Shareholderrechte: 3, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.